Cell Death & Disease , 15 (2), 145 Tang, Q., Fan, G., Peng, X., Sun, X., Kong, X., Zhang, L., Zhang, C., Liu, Y., Yang, J., Yu, K., Miao, C., Yao, Z., Li, L., Zhang, Z
Side effects of peptides can vary but may include allergic reactions, injection site reactions, and other individual-specific effects
Cell culture medium Stage 1 Medium: Base: iCDl medium (DMEM, 0.5 N2, 0.5 B27, 1% GlutaMAX, 1% NEAA, 1% sodium pyruvate, 0.1 mM 2-mercaptoethanol)
Use within the supplier-stated beyond-use window
[PMID: 8503872] PubMed record related to this compound for laboratory literature review
A randomized, double-blind, placebo-controlled, delayed start study to assess rasagiline as a disease modifying therapy in Parkinsons disease (the ADAGIO study): rationale, design, and baseline characteristics